General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GLLJY
ADC Name
AU2017363246B2 Conjugate53A
Synonyms
Conjugate53A
   Click to Show/Hide
Organization
MERSANA THERAPEUTICS, INC.
Drug Status
Investigative
Drug-to-Antibody Ratio
10.3
Structure
Antibody Name
XMT-1535
 Antibody Info 
Antigen Name
Sodium-dependent phosphate transport protein 2B (SLC34A2)
 Antigen Info 
Payload Name
AU2017363246B2+Conjugate53+Payload
 Payload Info 
Linker Name
AU2017363246B2+Conjugate53+Linker
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.01
nmol/L
CVCL_3941
Ovarian carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.01 nmol/L Negative her2 expression (her2-)
Method Description
OVCAR3 cell line was plated at 5,000cell/well in black walled 96-well plate and allowed to adhere overnight. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measured after 10 min using a SpectraMax M5 plate reader (Molecular Devices). Dose response curves were generated using SoftMax Pro software. IC50 values were determined from four-parameter curve fitting

   Click to Show/Hide
In Vitro Model Ovarian carcinoma OVCAR2 cells CVCL_3941
References
Ref 1 Peptide-containing linkers for antibody-drug conjugates